Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma

    Predicts survival in patients with metastatic renal cell carcinoma treated with systemic therapy (also known as Heng criteria).

    INSTRUCTIONS

    • Use baseline factors at the start date of the current line of systemic therapy, except for the “time of diagnosis to systemic therapy” criterion, which is always relative to first-line therapy.

    • Use limits of normal set by the laboratory performing the tests (for hemoglobin concentration, absolute neutrophil count, platelet count, corrected calcium concentration).

    • Always correct calcium concentration for low albumin before scoring.

    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with metastatic renal cell carcinoma.

    • Validated in the following settings:

      • Patients with clear cell and non-clear cell metastatic renal cell carcinoma.

      • Patients undergoing targeted therapies and immune checkpoint inhibitor therapy.

      • Multiple care settings: clinical trial patients, patients receiving standard of care therapy at community and academic centers, and across multiple countries.

    • Can assist in the choice of systemic therapy.

    • Easy to use, uses readily available clinical and laboratory variables, and compares favorably to other similar prognosis prediction models.

    Assists clinicians in discussions about prognosis and in deciding the appropriate systemic therapy for patients with metastatic renal cell carcinoma.

    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Daniel Heng

    About the Creator

    Daniel Heng, MD, MPH, is a staff medical oncologist at the Tom Baker Cancer Center in Calgary, Alberta, and a clinical professor of medicine at the University of Calgary. He holds a masters of public health from Harvard University and has a keen interest in outcomes, prognostic factors, and clinical trials research in kidney, bladder, prostate and testicular cancers. He is the chair of the Southern Alberta Genitourinary Tumor Group.

    To view Dr. Daniel Heng's publications, visit PubMed

    Are you Dr. Daniel Heng? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Dr. Toni Choueiri

    About the Creator

    Toni Choueiri, MD, is a medical oncologist and the director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital in Boston, Massachusetts. He is also co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. Dr. Choueiri's research interests include novel therapies and biomarkers in genitourinary malignancies.

    To view Dr. Toni Choueiri's publications, visit PubMed

    Are you Dr. Toni Choueiri? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Dr. Wanling Xie

    About the Creator

    Wanling Xie, PhD, is a biostatistician at the Dana-Farber Cancer Institute in Boston, Massachusetts. She has published and co-published dozens of peer-reviewed studies. Dr. Xie's research is mainly focused on genitourinary cancers, particularly metastatic renal cell carcinoma and prostate cancer.

    To view Dr. Wanling Xie's publications, visit PubMed

    Are you Dr. Wanling Xie? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    About the Creator
    Dr. Daniel Heng
    Are you Dr. Daniel Heng?
    Dr. Toni Choueiri
    Are you Dr. Toni Choueiri?
    Dr. Wanling Xie
    Are you Dr. Wanling Xie?
    Also from MDCalc...
    You might be interested in...
    Guidelines
    Renal Mass and Localized Renal Cancer

    Guideline from AUA

    Content Contributors